EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 62021TB0632
Case T-632/21: Order of the General Court of 1 March 2022 — Agreiter and Others v Commission (Action for annulment — Medicinal products for human use — Amendment of the conditional marketing authorisation for Spikevax, a medicinal product for human use — COVID-19 mRNA Vaccine (nucleoside modified) — No interest in bringing proceedings — Lack of direct concern — Lack of individual concern — Inadmissibility)
Case T-632/21: Order of the General Court of 1 March 2022 — Agreiter and Others v Commission (Action for annulment — Medicinal products for human use — Amendment of the conditional marketing authorisation for Spikevax, a medicinal product for human use — COVID-19 mRNA Vaccine (nucleoside modified) — No interest in bringing proceedings — Lack of direct concern — Lack of individual concern — Inadmissibility)
Case T-632/21: Order of the General Court of 1 March 2022 — Agreiter and Others v Commission (Action for annulment — Medicinal products for human use — Amendment of the conditional marketing authorisation for Spikevax, a medicinal product for human use — COVID-19 mRNA Vaccine (nucleoside modified) — No interest in bringing proceedings — Lack of direct concern — Lack of individual concern — Inadmissibility)
OJ C 198, 16.5.2022, p. 35–35
(GA)
OJ C 198, 16.5.2022, p. 50–51
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
16.5.2022 |
EN |
Official Journal of the European Union |
C 198/50 |
Order of the General Court of 1 March 2022 — Agreiter and Others v Commission
(Case T-632/21) (1)
(Action for annulment - Medicinal products for human use - Amendment of the conditional marketing authorisation for Spikevax, a medicinal product for human use - COVID-19 mRNA Vaccine (nucleoside modified) - No interest in bringing proceedings - Lack of direct concern - Lack of individual concern - Inadmissibility)
(2022/C 198/74)
Language of the case: German
Parties
Applicants: Karin Agreiter (Merano, Italy) and the 33 other applicants whose names are listed in the Annex to the order (represented by: R. Holzeisen, lawyer)
Defendant: European Commission (represented by: L. Haasbeek and B.-R. Killmann, acting as Agents)
Re:
By their action under Article 263 of the TFEU, the applicants seek annulment of Commission Implementing Decision C(2021) 5686 final of 23 July 2021 amending the conditional marketing authorisation for ‘Spikevax’ — COVID-19 mRNA Vaccine (nucleoside modified), a medicinal product for human use granted by Implementing Decision C(2021) 94 final of 6 January 2021.
Operative part of the order
|
1. |
The action is dismissed as inadmissible. |
|
2. |
There is no longer any need to adjudicate on the application for leave to intervene submitted by Moderna Biotech Spain SL. |
|
3. |
Ms Karin Agreiter and the other applicants whose names are listed in the Annex shall pay the costs. |
|
4. |
Moderna Biotech Spain shall bear its own costs related to the application for leave to intervene. |